Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
34
datasets available to search
ShareScore release 0.9.0
Dataset results
34 results for “Pharmaceutical Data”
S10 | SWISSPHARMA | Pharmaceutical List with Consumption Data
<p>This is the collection associated with list S10 SWISSPHARMA on the NORMAN Suspect List Exchange.</p> <p><a href="https://www.norman-network.com/nds/SLE/">https://www.norman-network.com/nds/SLE/</a></p> <p>S10 | SWISSPHARMA | <strong>Pharmaceutical List with Consumption Data</strong></p> <p>Table S2 from Singer <em>et al.</em> 2016. DOI: <a href="http://pubs.acs.org/doi/abs/10.1021/acs.est.5b03332">10.1021/acs.est.5b03332</a></p> <p>2024: added consumption data and mappings file for PubChem. </p>
Data and code for the analysis in "Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland"
<p>Data and code used for the analysis in <em>Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland</em> (Lemaitre et al., Swiss Medial Weekly 2020).</p>
Compound Data for Robust Processes for Polymer Modification and Pharmaceutical Synthesis
<p>Compound structural (IUPAC name, InChI, InChI Key, SMILES, .mol, .sdf) and spectral (NMR, MS) data included for compounds reported in the associated doctoral thesis. NMR data collected on Bruker Avance 400, 500, or 600 MHz spectrometers. Compound structure data were generated by ChemDraw v.20 (PerkinElmer). More details about the preparation and characterization of these compounds can be found in the associated thesis.</p>
Comparison of Drug Prescribing Before and During the COVID-19 Pandemic - A Cross-national European Study. Pharmaceuticals Consumption data
<p>Data and code supporting the article:</p> <p><strong>Comparison of Drug Prescribing Before and During the COVID-19 Pandemic - A Cross-national European Study </strong></p> <p>Prescription data from January 2017 to March 2021 for the Czech Republic, Germany, Lithuania, Slovenia, Spain (Catalonia), Sweden, and the United Kingdom (Scotland).<br>Data include the codes of the Anatomical-Therapeutic-Chemical classification (ATC) and corresponding numbers of dispensed defined daily doses (DDDs) and packs, aggregated by country, month and ATC.</p> <p>For more information, see the accompanying document ReadMe.txt.</p>
COVID-19 Non-Pharmaceutical Interventions: Data Annotation for Rapidly Changing Local Policy Information
<p><strong>Main Dataset Attributes (npi_data/*.xlsx)</strong></p> <ul> <li>FIPS: FIPS of the county.</li> <li>Location name: Name of the county.</li> <li>NPI measure: Type of NPI measure.</li> <li>Start Date: Date the NPI was first started.</li> <li>End Date: Date the NPI was first lifted.</li> <li>Start Link: Source link of the start date.</li> <li>End Link: Source link of the end date.</li> <li>Start Notes: Contains tags that apply to both dates, and the start date individually. Tag description can be found in Table 3. This also includes notes on nuances not included in the tags.</li> <li>End Notes. Contains tags that only apply to the end date go here. Tag description can be found in Table 3. This also includes notes on nuances not included in the tags.</li> <li>Validated (Correctness): Binary field indicating if the record was validated for correctness</li> </ul>
The impact of pharmaceutical form and simulated side effects in an open-label-placebo RCT for improving psychological distress in highly stressed students (Open Data and Open Materials)
<p> Open-label placebo (OLP) may be utilized to reduce psychological distress. Yet, potential contextual effects have not been explored. We investigated the impact of pharmaceutical form and the simulation of side effects in a parallel group RCT (DRKS00030987). A sample of 177 highly stressed university students at risk of depression were randomly assigned by computer generated tables to a one-week intervention with active or passive OLP nasal spray or passive OLP capsule or a no-treatment control group. After the intervention, groups differed significantly in depressive symptoms but not regarding other outcomes of psychological distress (stress, anxiety, sleep quality, somatization), well-being or treatment expectation. OLP groups benefitted significantly more compared to the no-treatment control group (<em>d</em>=.40), OLP nasal spray groups significantly more than the OLP capsule group (<em>d</em>=.40) and the active OLP group significantly more than the passive OLP groups (<em>d</em>=.42). Interestingly, before intervention, most participants, regardless of group assignment, believed that the OLP capsule would be most beneficial. The effectiveness of OLP treatments seems to be highly influenced by the symptom focus conveyed by the OLP rationale. Moreover, pharmaceutical form and simulation of side effects may modulate efficacy, while explicit treatment expectation seems to play a minor role.</p>
Data from: Pharmaceutical pollution alters the cost of bacterial infection and its relationship to pathogen load
<p><span>The relationship between pathogen proliferation and the cost of infection experienced by a host drives the ecology and evolution of host-pathogen dynamics. While environmental factors can shape this relationship, there is currently limited knowledge on the consequences of emerging contaminants, such as pharmaceutical pollutants, for the commonly observed trade-off between a pathogen's growth within the host and the damage it causes, termed its virulence. Here, we investigated how exposure to fluoxetine (Prozac), a commonly detected psychoactive pollutant, could alter this key relationship using the water flea <em>Daphnia magna</em> and its bacterial pathogen <em>Pasteuria ramosa </em>as a model system. Across a variety of fluoxetine concentrations, we found that fluoxetine shaped the damage a pathogen caused, such as the reduction in fecundity or intrinsic growth experienced by infected individuals, but with minimal change in average pathogen spore loads. Instead, fluoxetine modified the relationship between the degree of pathogen proliferation and its virulence, with both the strength of this trade-off and the component of host fitness most affected varying by fluoxetine concentration and host genotype. Our study underscores the potential for pharmaceutical pollution to modify the virulence of an invading pathogen, as well as the fundamental trade-off between host and pathogen fitness, even at the trace amounts increasingly found in natural waterways. </span></p>
NMR data for "Application of a Hydrophobic Polyglutamate Bearing a Triphenylphosphine Group for the Orientation of Pharmaceutically Active Compounds and the Measurement of Residual Dipolar Couplings"
<p>NMR raw data for the work titled:</p> <p>"Application of a Hydrophobic Polyglutamate Bearing a Triphenylphosphine Group for the Orientation of Pharmaceutically Active Compounds and the Measurement of Residual Dipolar Couplings"</p> <p>The archive consists of NMR spectra of all compounds synthesized and the NMR spectra used for the determination of RDCs (isotropic and anisotropic).</p>
A letter to the Lancet Planetary Health: Assessment from our world in data of overall gain in mortality after COVID pharmaceutical intervention
<p>Straightforward comparison of COVID mortality before and after the pharmaceutical intervention as recovered from the site https://ourworldindata.org/explorers/coronavirus-data-explorer</p> <p>Submitted as a letter to Lancet Planetary Health</p>
Raw Data for the article: Efficacy of Three Commercial Disinfectants in Reducing Microbial Surfaces' Contaminations of Pharmaceuticals Hospital Facilities
<p>To evaluate and validate the efficacy of disinfectants used in our cleaning procedure, in order to reduce pharmaceutical hospital surfaces' contaminations, we tested the action of three commercial disinfectants on small representative samples of the surfaces present in our hospital cleanrooms. These samples (or coupons) were contaminated with selected microorganisms for the validation of the disinfectants. The coupons were sampled before and after disinfection and the microbial load was assessed to calculate the Log<sub>10</sub> reduction index. Subsequently, we developed and validated a disinfection procedure on real surfaces inside the cleanrooms intentionally contaminated with microorganisms, using approximately 10<sup>7</sup>-10<sup>8</sup> total colony forming units per coupon. Our results showed a bactericidal, fungicidal, and sporicidal efficacy coherent to the acceptance criteria suggested by United States Pharmacopeia 35 <1072>. The correct implementation of our cleaning and disinfection procedure, respecting stipulated concentrations and contact times, led to a reduction of at least 6 Log<sub>10</sub> for all microorganisms used. The proposed disinfection procedure reduced the pharmaceutical hospital surfaces' contaminations, limited the propagation of microorganisms in points adjacent to the disinfected area, and ensured high disinfection and safety levels for operators, patients, and treated surfaces.</p>
Mass spectrometric investigation of pharmaceuticals in environmental matrices - homogenate analysis: Thesis Data 2
<p>RT Thesis - Mass spectrometric investigation of pharmaceuticals in environmental matrices - homogenate analysis_data set 4 contains Mass Lynx data sets part 2</p> <p> </p> <p>RT Thesis - Mass spectrometric investigation of pharmaceuticals in environmental matrices - homogenate analysis_data set 5 contains Mass Lynx data sets part 3</p>
Data for "Vaccinations or Non-Pharmaceutical Interventions:Safe Reopening of Schools in England"
<p>This dataset contains the output files generated with the JUNE epidemiological model use to produce the paper "Vaccinations or Non-Pharmaceutical Interventions:Safe Reopening of Schools in England" https://doi.org/10.1101/2021.09.07.21263223</p>
LC-MS/MS data of pharmaceutical compounds for lIbrary building
<p>Dataset used for MergeION package testing are provided by Janssen Pharmaceutica. It consists of known standard pharmaceutical compounds for which high quality Q-Exactive MS/MS data is provided. Details about these compounds can be found in Metadata_Library.txt. All datasets were acquired in positive ion mode through either DDA (data-dependent acquisition) or targeted MS/MS. Raw data in profile mode were converted into centroid-mode mzML or mzXML files using MSConvertGUI</p> <p> </p>
DATA: molecularly enhanced proof of concept for targeting cocrystals at molecular scale in continuous pharmaceuticals cocrystallization - part 2
<p>This is the cleansed files for CoCryM project carried out at the University of Limerick, Ireland for a MSCA postdoctoral fellowship. </p> <p>Link to PNAS paper <a href="https://www.pnas.org/doi/10.1073/pnas.2114277119">https://www.pnas.org/doi/10.1073/pnas.2114277119</a> </p> <p>(molecularly enhanced proof of concept for targeting cocrystals at molecular scale in continuous pharmaceuticals cocrystallization) </p> <p>Original uploaded files on 10 September 2021: </p> <ol> <li><a href="https://doi.org/10.5281/zenodo.6164838">https://doi.org/10.5281/zenodo.6164838</a></li> <li><a href="https://doi.org/10.5281/zenodo.6189068">https://doi.org/10.5281/zenodo.6189068</a></li> <li><a href="https://doi.org/10.5281/zenodo.6189100">https://doi.org/10.5281/zenodo.6189100</a></li> <li><a href="https://doi.org/10.5281/zenodo.6189715">https://doi.org/10.5281/zenodo.6189715</a></li> <li><a href="https://doi.org/10.5281/zenodo.6189885">https://doi.org/10.5281/zenodo.6189885</a></li> </ol> <p> </p> <p>Inhouse: https://sites.google.com/view/makhansary/publications </p>
Small intestinal microbiota data of pigs receiving control or pharmaceutical levels of ZincOxide
<p>To improve our understanding of host and intestinal microbiome interaction, this research investigated the effects of a high level zinc oxide in the diet as model intervention on the intestinal microbiome and small intestinal functionality in clinically healthy post-weaning piglets.</p> <p>In study 1 piglets received either a high concentration of zinc as zinc oxide (Zn, 2690 mg/kg) or a low Zn concentration (100 mg/kg) in the diet during the post weaning period (d 14-23). We investigated the effects on the piglet’s small intestinal microbiome and functionality of intestinal tissue. In study 2 we investigated the impact of timing of the dietary zinc intervention, i.e. between d 0-14 and/or d 14-23 post weaning, and the consecutive effects on the piglet’s intestinal functionality. We acquired data on the microbiota composition in small intestinal digesta and gene expression profiles of both jejunum and ileum tissue.</p> <p>Overall, we observed differences in the small intestinal functionality during the post weaning period between piglets receiving a diet with a low or high concentration ZnO content.</p>
Data from: Pharmaceutical pollution alters the cost of bacterial infection and its relationship to pathogen load
Open the record for dataset details and reuse information.
Baltimore Ecosystem Study polar organic contaminant integrative sampler data for pharmaceuticals and personal care products in core sites within Gwynns Falls watershed and reference sites.
An ongoing component of the Baltimore urban long-term ecological research (LTER) project (Baltimore Ecosystem Study, BES) is the use of the watershed approach and monitoring of stream water quality to evaluate the impacts of multiple chemical stressors on urban stream ecosystem functioning within Baltimore. The LTER research has focused on the Gwynns Falls watershed, which spans a gradient from highly urban, urban-residential, and suburban zones. In addition, a forested watershed serves as a reference. The long-term sampling network includes four longitudinal sampling sites along the Gwynns Falls mainstem, as well as several small (40-100 ha) watershed within or near the Gwynns Falls, providing data on water quality in different land use zones of the watersheds. Each study site is continuously monitored for discharge and is sampled weekly for water chemistry. Those data are available elsewhere on the BES website. We are interested in studying the presence and concentrations of pharmaceuticals and personal care products (PPCPs) within urban streams, and then linking these PPCPs with various stream ecosystem functions. To quantify the concentrations of PPCPs in streams, we deploy polar organic contaminant integrative samples (POCIS), which integrate all organic contaminants that pass by them in a stream over a set period of deployment. These POCIS allow us to integrate the total amount of PPCPs within a stream over a set period of time, and then to relate these concentrations with other ecosystem processes. We monitored PPCP concentration in four suburban to urban sites within the Gwynns Falls, as well as one exurban and one forested stream monitoring site. Each POCIS was deployed for two weeks at a stream monitoring site in March 2012. After completion of the sampling period, POCIS were removed from the streams and shipped on ice to the University of Nebraska for extraction and quantification of recovered compounds. This dataset includes all compounds extracted and q
Data from: Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices
Objectives: To develop and pilot a tool to measure and improve pharmaceutical companies' clinical trial data sharing policies and practices. Design: Cross sectional descriptive analysis. Setting: Large pharmaceutical companies with novel drugs approved by the US Food and Drug Administration in 2015. Data sources: Data sharing measures were adapted from 10 prominent data sharing guidelines from expert bodies and refined through a multi-stakeholder deliberative process engaging patients, industry, academics, regulators, and others. Data sharing practices and policies were assessed using data from ClinicalTrials.gov, Drugs@FDA, corporate websites, data sharing platforms and registries (eg, the Yale Open Data Access (YODA) Project and Clinical Study Data Request (CSDR)), and personal communication with drug companies. Main outcome measures: Company level, multicomponent measure of accessibility of participant level clinical trial data (eg, analysis ready dataset and metadata); drug and trial level measures of registration, results reporting, and publication; company level overall transparency rankings; and feasibility of the measures and ranking tool to improve company data sharing policies and practices. Results: Only 25% of large pharmaceutical companies fully met the data sharing measure. The median company data sharing score was 63% (interquartile range 58-85%). Given feedback and a chance to improve their policies to meet this measure, three companies made amendments, raising the percentage of companies in full compliance to 33% and the median company data sharing score to 80% (73-100%). The most common reasons companies did not initially satisfy the data sharing measure were failure to share data by the specified deadline (75%) and failure to report the number and outcome of their data requests. Across new drug applications, a median of 100% (interquartile range 91-100%) of trials in patients were registered, 65% (36-96%) reported results, 45% (30-84%) were published, and 95% (69-100%) were publicly available in some form by six months after FDA drug approval. When examining results on the drug level, less than half (42%) of reviewed drugs had results for all their new drug applications trials in patients publicly available in some form by six months after FDA approval. Conclusions: It was feasible to develop a tool to measure data sharing policies and practices among large companies and have an impact in improving company practices. Among large companies, 25% made participant level trial data accessible to external investigators for new drug approvals in accordance with the current study's measures; this proportion improved to 33% after applying the ranking tool. Other measures of trial transparency were higher. Some companies, however, have substantial room for improvement on transparency and data sharing of clinical trials.
Data from: Water-borne pharmaceuticals reduce phenotypic diversity and response capacity of natural phytoplankton communities
Chemical micropollutants occur worldwide in the environment at low concentrations and in complex mixtures, and how they affect the ecology of natural systems is still uncertain. Dynamics of natural communities are driven by the interaction between individual organisms and their growth environment, which is mediated by the organisms' expressed phenotypic traits. We tested whether exposure to a mixture of 12 pharmaceuticals and personal care products (PPCP) influences phenotypic trait diversity in lake phytoplankton communities and their ability to regulate biomass production to fit environmental changes (response capacity). We exposed natural phytoplankton assemblages to three mixture levels in permeable microcosms maintained at three depths in a eutrophic lake for one week, during which the environmental conditions were fluctuating. We studied individual-level traits, phenotypic diversity and community biomass. PPCP reduced individual-level trait variance and overall community phenotypic diversity, but maintained higher standing phytoplankton biomass compared to untreated controls. Estimated effect sizes of PPCP on traits and community properties were very large (partial Eta-squared > 0.15). The PPCP mixture antagonistically interacted with the natural environmental gradient in habitats offered by different depths and, at concentrations comparable to those in waste-water effluents, prevented communities from converging to the same phenotypic structure and total biomass of unexposed controls. We show that micropollutants can alter individual-level trait diversity of lake phytoplankton communities and therefore their capacity to respond to natural environmental gradients, potentially affecting aquatic ecosystem processes.
Data from: Simultaneous determination of diosmin and hesperidin in combined pharmaceutical preparation by synchronous fluorescence spectrofluorimetric method
<p>Diosmin (DSM) and hesperidin (HSP) binary mixture was analyzed simultaneously by developing a sensitive, rapid, and simple synchronous spectrofluorimetric method. In methanol at ∆λ of 100 nm, the relative synchronous fluorescence intensities (RSFI) of both medications were measured. It was shown that these intensities were influenced by distinct experimental factors. The optimization and detailed study of these parameters were conducted. For DSM and HSP, respectively, the plots of synchronous fluorescence intensity-concentration were found to be rectilinear across the ranges of 0.5-5.0 µg/mL and 0.2-3.0 µg/mL. For DSM and HSP, respectively, 0.107 µg/mL and 0.048 µg/mL were the detection limits and 0.323 and 0.144 µg/mL were the limits of quantification. The method described in this study was effectively employed to estimate the quantities of both drugs present in commercially available mixed tablets. The results produced using this method were then compared favorably to results obtained using a different method for comparison.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.